SCHEMBL22650348

SCHEMBL22650348

CC(C)(C)OC(=O)N1CCN(c2ccc(N)c(O)c2)C(=O)C1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
ESR2 Q92731 1/20 0.44
SMARCA2 P51531 2/20 0.44
SMARCA4 P51532 2/20 0.44
PBRM1 Q86U86 2/20 0.44
GPR119 Q8TDV5 4/20 0.39
ADORA1 P30542 1/20 0.39
NAMPT P43490 1/20 0.39
ENPP2 Q13822 2/20 0.39
MAPK1 P28482 1/20 0.39
USP30 Q70CQ3 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29709677 1.00 NR1H2 (0.46) NR1H2MAPTALDH1A1LMNAESR2
SCHEMBL29990901 0.88 MAPT (0.46) NR1H2MAPTALDH1A1LMNAESR2
SCHEMBL22650415 0.88 MAPT (0.46) NR1H2MAPTALDH1A1LMNAESR2
SCHEMBL26629245 0.87 NR1H2 (0.46) NR1H2MAPTALDH1A1LMNAESR2
SCHEMBL22650491 0.87 NR1H2 (0.46) NR1H2MAPTALDH1A1LMNAESR2
SCHEMBL3312798 0.86 MAPT (0.45) NR1H2MAPTALDH1A1LMNAESR2
SCHEMBL31129834 0.86 NR1H2 (0.46) NR1H2MAPTALDH1A1LMNAESR2
SCHEMBL1583728 0.85 ESR2 (0.44) NR1H2MAPTALDH1A1LMNAESR2
SCHEMBL26629389 0.84 MAPT (0.43) NR1H2MAPTALDH1A1LMNAESR2
SCHEMBL1583382 0.84 ESR2 (0.52) NR1H2MAPTALDH1A1LMNAESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402901-A1 SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS BIAL R&D INVEST S A (PT) 2022-12-22 US disclosed
CN-114761386-A Substituted N-heterocyclic carboxamides as acid ceramidase inhibitors and their use as pharmaceuticals 比亚尔R&D投资股份公司 2022-07-15 CN disclosed
WO-2020224568-A1 CDK INHIBITORS QILU REGOR THERAPEUTICS INC. (CN) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402901-A1 SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS ASAH2, ASAH1, GBA1 NR1H2 3126/4885MAPT 1369/4885ALDH1A1 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.